 Prostate specific antigen critical assessment useful tumor marker adenocarcinoma prostate PSA kallikrein-like serine protease epithelial cells types prostatic tissue benign malignant present seminal fluid high concentration functions high molecular weight protein responsible seminal coagulum polypeptides action results liquefaction coagulum PSA present serum monoclonal immunoradiometric assay polyclonal radioimmunoassay calculated half-life serum PSA days metabolic clearance rate tumor marker first-order kinetics Digital rectal examination cystoscopic examination biopsy spurious elevations serum PSA concentration Conditions bacterial prostatitis acute urinary retention serum PSA level patients BPH serum PSA concentration BPH tissue PSA value variable manner patient patient unlikely PSA effective screening tool early diagnosis prostate cancer digital rectal examination transrectal vital part early detection program Prostatic intraepithelial neoplasia serum PSA levels direct correlation serum PSA concentration clinical stage PSA reliable clinical stage individual basis finding pathological stage result preoperative serum PSA concentration radical prostatectomy potential cure Low preoperative serum PSA concentrations patients prostate cancers predictive negative bone scan select patients bone scintigram necessary respect monitoring patients definitive therapy PSA sensitive tumor marker Irrespective treatment modality radical prostatectomy radiation therapy antiandrogen treatment PSA tumor status patient prognostic eventual outcome tumor marker capable tumor recurrence months detection method PSA useful immunocytochemical marker sensitivity specificity tissue prostatic origin approach PAP PSA precise meaningful marker clinical situations ABSTRACT TRUNCATED AT WORDS